UBS Maintains Neutral on Clover Health Investments, Raises Price Target to $5.5

Benzinga · 2d ago
UBS analyst Jonathan Yong maintains Clover Health Investments (NASDAQ:CLOV) with a Neutral and raises the price target from $5 to $5.5.